Letter to the editor

DOI: 10.4244/EIJ-D-24-00560

Letter: Identifying vulnerable coronary atherosclerotic plaques: from theory to practice

Kyriakos Dimitriadis1, MD, PhD, FESC; Nikolaos Pyrpyris, MD; Konstantinos Tsioufis, MD, PhD, FESC

We read with great interest the study by del Val et al1 regarding the prognostic role of vulnerable plaque features in non-ischaemic lesions, showing thin-cap fibroatheroma (TCFA) as the strongest predictor of future events, with the addition of other vulnerable plaque parameters further increasing this risk. This study is of particular importance; however, several key insights must be highlighted.

Firstly, 68.4-84.4% of patients received statins, with significantly lower use in most subgroups with high-risk characteristics, compared to patients without. Furthermore, there is no report of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor use. It is well documented that PCSK9 inhibitors lead to plaque regression and stabilisation2. Notably, a phenotype of “triple regression” − which consists of the combined presence of (a) percentage of atheroma volume reduction, (b) maximum lipid core burden index within 4 mm reduction and (c) minimal fibrous cap thickness increase − is significantly associated with fewer adverse outcomes and independently associated with the use of PCSK9 inhibitors3. Given the prognostic significance of both vulnerable plaques and the presence of plaque regression, as well as the...

Sign in to read
the full article

Forgot your password?
No account yet?
Sign up for free!

Create my pcr account

Join us for free and access thousands of articles from EuroIntervention, as well as presentations, videos, cases from PCRonline.com

Volume 20 Number 16
Aug 19, 2024
Volume 20 Number 16
View full issue


Key metrics

Trending articles
167.55

Expert review

10.4244/EIJ-D-21-00690 May 15, 2022
Crush techniques for percutaneous coronary intervention of bifurcation lesions
Moroni F et al
free
73.05

State-of-the-Art

10.4244/EIJ-D-24-00386 Feb 3, 2025
Mechanical circulatory support for complex, high-risk percutaneous coronary intervention
Ferro E et al
free
60.55

State-of-the-Art

10.4244/EIJ-D-24-00066 Apr 21, 2025
Management of complications after valvular interventions
Bansal A et al
free
58.3

Clinical research

10.4244/EIJ-D-23-00344 Sep 18, 2023
Clinical outcomes of TAVI with the Myval balloon-expandable valve for non-calcified aortic regurgitation
Sanchez-Luna JP et al
free
33.9

CLINICAL RESEARCH

10.4244/EIJ-D-17-00381 Oct 11, 2017
Stent malapposition and the risk of stent thrombosis: mechanistic insights from an in vitro model
Foin N et al
free
33.65

State-of-the-Art

10.4244/EIJ-D-23-00606 Jan 1, 2024
Targeting inflammation in atherosclerosis: overview, strategy and directions
Waksman R et al
free
26

Expert Review

10.4244/EIJ-D-24-00535 May 5, 2025
Catheter-based techniques for pulmonary embolism treatment
Costa F et al
23.55

Expert Review

10.4244/EIJ-D-23-00700 Feb 19, 2024
Evolving indications for transcatheter mitral edge-to-edge repair
Shuvy M and Maisano F
free
X

The Official Journal of EuroPCR and the European Association of Percutaneous Cardiovascular Interventions (EAPCI)

EuroPCR EAPCI
PCR ESC
Impact factor: 7.6
2023 Journal Citation Reports®
Science Edition (Clarivate Analytics, 2024)
Online ISSN 1969-6213 - Print ISSN 1774-024X
© 2005-2025 Europa Group - All rights reserved